#JPM25 live blog day 2: Nvidia makes it fun; The year’s 10th megaround

We just wrapped day 2 of JPM.

We’ve been paying close attention to news about the industry’s biggest drugmakers.

Jaimy Lee had a

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Nirsevimab shows 90% success in shielding infants from RSV hospitalizations

Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination’s role in offering protection.

March 11, 2024

Secretive Treeline Biosciences discloses $421M financing in filing

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 18, 2024

Failed clinical trials don’t always spell doom for a new drug. Here’s why

This article was adapted from STAT’s latest report, “Failed trial, successful drug: how a negative readout can still lead to FDA approval.” When a clinical

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.